
Introduction and Key Questions
All patients should be considered for entry into clinical trials when available. See the Clinical Trials page on the Intranet.
Key questions to be answered before giving intensive treatment to a newly diagnosed patient with ALL:
- Is high intensity treatment appropriate?
- Is the patient Philadelphia-positive?
- Ph- ALL between ages 15-30 should be considered for a paediatric chemotherapy protocol.
- Ph+ ALL should be treated with a regimen containing a tyrosine kinase inhibitor (i.e. imatinib or dasatinib), preferably within a clinical trial.
The following important differences exist when ALL is compared to AML:
- CNS disease is common in ALL. All the above protocols require that CSF be examined either before treatment starts or early during remission induction.
- Tyrosine kinase inhibitor treatment (i.e. imatinib or dasatinib) – The tyrosine kinase inhibitor forms a crucial part of managing Ph+ ALL patients.
Topic Code: 8848